Plasma cell-directed therapies induce profound clinical and durable responses in patients with severe or relapsed/refractory scleromyxedema.
F ThevesC LahunaThibault MahevasS HarelB RoyerV LemialeA BrignierN ParquetMarie JachietJean-David BouazizD ElessaB ArnulfAlexis TalbotPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
The association of lenalidomide and dexamethasone with HDIVIg could improve the treatment of relapsed or severe SM.